Immunovant's IMVT-1402 Posts 72.7% ACR20 in D2T RA Trial, Batoclimab Development Halted
summarizeSummary
Immunovant reported strong preliminary Week 16 results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (D2T RA), showing 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates, alongside a favorable safety profile. Concurrently, the company announced the discontinuation of its batoclimab program across all indications following the failure of two Phase 3 thyroid eye disease (TED) studies, incurring a $39.0 million charge in the fourth quarter. The company's cash and cash equivalents stood at $902.1 million as of March 31, 2026, providing runway through the potential commercial launch of IMVT-1402 in Graves' Disease. This positive clinical data for IMVT-1402, a key pipeline asset, is a significant catalyst for the clinical-stage biotech, validating its potential and allowing for a strategic focus shift. The robust cash position further supports the accelerated development of IMVT-1402. Investors should monitor upcoming updates on the IMVT-1402 D2T RA program and topline data from the CLE trial in the second half of 2026, as well as registrational trial data for GD and MG expected in 2027.
At the time of this announcement, IMVT was trading at $31.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.79 to $30.16. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.